Take-Two Interactive (TTWO - Free Report) closed at $203.74 in the latest trading session, marking a -1.96% move from the prior day. This change lagged the S&P 500's 0.52% loss on the day. At the same time, the Dow lost 1.24%, and the tech-heavy Nasdaq lost 0.21%.
The publisher of "Grand Theft Auto" and other video games's stock has climbed by 2.38% in the past month, falling short of the Consumer Discretionary sector's gain of 4.8% and outpacing the S&P 500's loss of 1.21%.
Investors will be eagerly watching for the performance of Take-Two Interactive in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on November 9, 2026. The company's earnings per share (EPS) are projected to be $0.9, reflecting a 38.36% decrease from the same quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $1.66 billion, indicating a 15.42% decrease compared to the same quarter of the previous year.
TTWO's full-year Zacks Consensus Estimates are calling for earnings of $6.99 per share and revenue of $8.53 billion. These results would represent year-over-year changes of +70.49% and +26.97%, respectively.
Investors might also notice recent changes to analyst estimates for Take-Two Interactive. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Currently, Take-Two Interactive is carrying a Zacks Rank of #3 (Hold).
In the context of valuation, Take-Two Interactive is at present trading with a Forward P/E ratio of 29.71. This expresses a premium compared to the average Forward P/E of 15.85 of its industry.
We can also see that TTWO currently has a PEG ratio of 1.09. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. Gaming stocks are, on average, holding a PEG ratio of 1.09 based on yesterday's closing prices.
The Gaming industry is part of the Consumer Discretionary sector. This industry, currently bearing a Zacks Industry Rank of 202, finds itself in the bottom 18% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
New York, New York--(Newsfile Corp. - October 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hyliion Holdings Corp. (NYSE American: HYLN) between May 12, 2026 and June 23, 2026, both dates inclusive (the "Class Period"), of the important October 27, 2026 lead plaintiff deadline. SO WHAT: If you purchased Hyliion common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Shares of membership-based warehouse retailer Costco Wholesale (COST -1.46%) trade near $1,010 as I write, nearly 8% under the record close of $1,094.32 they set on May 19.
The company behind the stock keeps delivering. Costco's earnings per share grew 14% in fiscal 2026 (the 52 weeks ending Aug. 30, 2026), faster than the 10% increase a year earlier. And net sales climbed 10% to around $297 billion.
What might $5,000 put in the stock now be worth by the end of 2030?
With a forecast based on earnings growth, a lower valuation multiple, and the dividend, I get around $6,350. It's a decent gain. But the same $5,000 in an index fund matching the long-term average of the S&P 500 (^GSPC -0.52%) might reach around $7,450.
Image source: Getty Images.
How fast can earnings grow?Costco's fiscal 2026 earnings included a one-time boost of $0.15 a share from tariff refunds in the fiscal fourth quarter. Without that, the company earned around $20.61 a share, still about 13% above fiscal 2025's $18.21.
Earnings per share were $11.27 in fiscal 2021, so this rate matches their average growth of around 13% a year for the last five years.
But the next few years likely won't match it. Costco hiked its yearly membership fees in the U.S. and Canada on Sept. 1, 2024, and it records that income gradually over each member's year. The higher fees made up around 30% of the 11% growth in membership fee revenue in fiscal 2026, according to Costco's annual report. By the fiscal fourth quarter, membership fee income was up only about 7% year over year.
That matters because membership fees brought in around $5.9 billion last fiscal year, or about half of Costco's $11.7 billion in operating income.
The rest of the business still has room to grow, of course. Comparable sales excluding gas prices and foreign exchange climbed 6.6% in fiscal 2026, and Costco plans to open up to 33 warehouses in fiscal 2027, including five relocations.
I'll assume earnings per share grow around 11% a year from here, a step down from the last five years but still a solid rate. That puts fiscal 2030 earnings per share at about $31.30.
Costco's valuation might come downThe price investors pay for these earnings arguably counts just as much. At around $1,010, Costco stock trades at about 49 times fiscal 2026 earnings. At the end of fiscal 2023, the stock fetched about 38 times that year's earnings of $14.16 per share.
I'll assume the price-to-earnings ratio lands at 40 times earnings by the end of 2030. That's still a premium price for a retailer, and I think it's fair for a business growing earnings roughly 11% a year.
At 40 times fiscal 2030 earnings of about $31.30, Costco stock would trade near $1,250. Now, $5,000 gets about 4.95 shares, so the stake might be worth around $6,190.
Costco also pays a dividend of $1.47 per share a quarter, after lifting it 13% in April. If the payout keeps climbing around 11% a year, in line with earnings, the 4.95 shares might collect a bit over $150 in regular dividends by the end of 2030 (I'm not counting any special dividends). That takes the total to around $6,350, a gain of about 6% a year.
COST Costco Wholesale$1,003.32-$14.89 (-1.46%)
NASDAQ · As of 4:00 PM ET 10/23/26
An index fund might do betterWith dividends, the S&P 500 has returned about 10% a year since 1928. At that rate, $5,000 put in the index through a fund on Oct. 23 could rise to about $7,450 by the end of 2030 -- about $1,100 more than my Costco forecast.
Then again, the market could return less than its long-run average in the next few years. And Costco's price-to-earnings ratio may not come down at all. The stock closed each of the last three fiscal years at more than 45 times earnings. But for Costco to keep up with the index fund, it'd have to trade at about 47 times earnings at the end of 2030, near where it trades today, while still growing earnings 11% a year.
Put another way, the company might do everything I'm assuming, and the stock could still trail the market if investors pay a bit less for every dollar Costco earns.
I think the warehouse club is still one of the best retailers to own for the long run, and I'd be comfortable adding shares slowly over time. But I wouldn't expect the stock to beat an index fund from here.
Now with a new route of induction administration, subcutaneous SKYRIZI supports early symptomatic and endoscopic control with an on-body injector (OBI) device throughout the course of treatmentIn the pivotal Phase 3 AFFIRM study, subcutaneous (SC) SKYRIZI® achieved superior clinical remissioni and endoscopic responseii at week 12 compared with placebo in patients with Crohn's disease; results were particularly strong in patients without prior advanced therapy failureiiiThe safety profile of subcutaneous induction was generally consistent with the established SKYRIZI profile in Crohn's disease, with no new safety risks identifiedFDA also approved an update to the U.S. Prescribing Information warning and precautions across all indications to allow healthcare providers to use clinical judgment when determining whether tuberculosis (TB) testing is needed, /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for SKYRIZI® (risankizumab-rzaa) for adults with moderately to severely active Crohn's disease (CD)iv. Patients now have the option to start SKYRIZI treatment at home, with induction doses delivered by an on-body injector (OBI) induction pack and then continue using an OBI once every eight weeks throughout the course of maintenance treatment.
"People living with Crohn's disease need treatments that can deliver meaningful disease control from the start," said Roopal Thakkar, M.D., executive vice president, research and development, chief scientific officer, AbbVie. "With the approval of subcutaneous induction, we are building on the strong efficacy of SKYRIZI while giving patients and physicians greater flexibility in how treatment is initiated. This is one more example of how AbbVie continues to advance treatment to better meet the needs of people living with Crohn's disease."
Subcutaneous SKYRIZI Shows High Rates of Clinical Remission and Endoscopic Response by Week 12iii
This FDA approval is supported by positive results from the Phase 3 AFFIRM trial evaluating the efficacy and safety of SC SKYRIZI versus placebo in patients with moderately to severely active CD.iii SKYRIZI achieved superiority of the co-primary endpoints of clinical remission and endoscopic response at week 12.iii Although the study enrolled a primarily treatment-refractory population, these Phase 3 results were particularly strong within patients without prior advanced therapy failure (advanced therapy-naïve).iii By week 12, nearly three-quarters (74%) of advanced therapy (AT)-naïve patients were in clinical remission (vs. 27% placebo) and these AT-naïve patients achieved endoscopic response at four times the rate of placebo (60% vs. 15%, respectively).iii SC SKYRIZI also had a higher efficacy response in patients who had previously failed advanced therapy.iii
SC SKYRIZI also met secondary endpoints including endoscopic remission and FACIT fatigue scores at week 12 vs. placebo.iii The safety profile of SC SKYRIZI for induction was generally consistent with its known profile in CD, with no new safety risks observed.iii
Together, these results demonstrate market-leading clinical and endoscopic outcomes in advanced therapy-naïve patients that set a high bar in CD. Furthermore, the strength of these subcutaneous results provides a compelling foundation for future clinical trials.
AFFIRM Phase 3 Proportion of Patients Meeting Efficacy Endpoints at Week 12iii
Total Population
Prior Advanced Therapy
Failurea
Without Prior Advanced
Therapy Failureb
(Advanced Therapy-Naïve)
Proportion of
Patients
Placebo
N=94
Skyrizi SCc
N=180
Placebo
N=61
Skyrizi SCc
N=115
Placebo
N=33
Skyrizi SCc
N=65
Clinical
Remissiond,e
30 %
56 %h
31 %
45 %
27 %
74 %
Endoscopic
Responsed,f
15 %
43 %h
15 %
33 %
15 %
60 %
Endoscopic
Remissiong
11 %
26 %h
11 %
17 %
9 %
43 %
a. Prior advanced therapy failure includes inadequate response, loss of response, or intolerance to one or more biologic or Janus Kinase inhibitor (JAKi) treatments for CD
b. Without prior advanced therapy failure includes patients who were naïve to biologics or JAKi, or patients who had never failed or demonstrated intolerance to biologics or JAKi
c. SKYRIZI 720 mg as a subcutaneous injection at Week 0, Week 2, Week 4, and Week 8
d. Co-primary endpoints
e. Defined as Crohn's disease activity index (CDAI) < 150
f. Defined as a decrease in Simplified Endoscopic Activity Score for Crohn's disease (SES-CD) > 50% from baseline, or a decrease of at least 2 points for subjects with a baseline
score of 4 and isolated ileal disease, based on central reading
g. SES-CD ≤ 4 and at least a 2-point reduction from baseline, with no individual subscore greater than 1, based on central reading
h. p <0.001 compared to placebo in total population.
Subcutaneous Treatment With SKYRIZI Offers Fully Self-Administered Therapy From the Start
The induction dosing regimen with SC SKYRIZI is 720 mg delivered by OBI induction pack at weeks 0, 2, 4 and 8.iii Patients also have the option to start treatment intravenously with 600 mg delivered at weeks 0, 4 and 8.iii Patients can then continue with maintenance dosing starting at week 12 administered by OBI every eight weeks.iii
"When patients and I discuss treatment, they want to know two things: will it work? And how will it fit into their lives?" said Millie D. Long, M.D., MPH, chief, division of gastroenterology and hepatology, University of North Carolina at Chapel Hill, and lead investigator of AFFIRM. "AFFIRM answered the first question, with superior rates of clinical remission and endoscopic response versus placebo during induction with subcutaneous SKYRIZI, particularly in patients new to advanced therapy. This approval answers the second. As a physician who has used the SKYRIZI OBI, I've seen firsthand the convenience it can offer patients. Now with this approval, patients can start treatment at home and continue the same way through maintenance."
Patients Report Satisfaction and Ease of Use in Real World Experience With SKYRIZI OBI
First introduced in 2022 for CD maintenance treatment, the SKYRIZI OBI has demonstrated strong user experience. In a real-world survey of 186 people living with CD, 88% reported AbbVie's OBI easy to use.v In evaluating alternative routes of administration, a patient-reported survey of 352 adults living with IBD found 87% were satisfied or highly satisfied with OBI compared to 71% with an autoinjectorvi, demonstrating patient preference for OBI.
FDA Also Approved Update to Tuberculosis (TB) Language in U.S. Prescribing Information
Additionally, the FDA approved an update to the SKYRIZI prescribing information's warning and precautions language across all approved indications.iii The revised label advises healthcare providers to consider TB evaluation prior to treatment initiation based on clinical judgment.iii This change gives healthcare providers greater flexibility in patient assessment before starting SKYRIZI treatment. There is no mandatory TB test prior to initiating SKYRIZI.
About Crohn's Disease
Crohn's disease is a chronic, systemic disease that manifests as inflammation within the gastrointestinal tract, most commonly in the area between the small intestine (ileum) and the colon, causing persistent diarrhea and abdominal pain.vii,viii It is a progressive disease, meaning it gets worse over time and may lead to life-threatening complications or surgery.ix,x Because the signs and symptoms of Crohn's disease are unpredictable, it causes a significant burden on people living with the disease—not only physically but also emotionally and economically.xi
About the AFFIRM Studyxii
AFFIRM is a global, Phase 3, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of risankizumab subcutaneous (SC) as an induction treatment in adult patients with moderately to severely active Crohn's disease. Co-primary endpoints were percentage of participants with CDAI Clinical Remission (CDAI < 150) and percentage of participants with endoscopic response at week 12. A total of 274 patients were randomized in a 2:1 ratio to risankizumab SC or placebo. Key demographics and baseline characteristics were generally balanced between the risankizumab SC and placebo groups; 65% had failed advanced therapies for the treatment of CD before. The study consists of three treatment periods: a placebo-controlled Period A (baseline to week 12) to evaluate the efficacy and safety of risankizumab SC induction treatment, an extended Period B (week 12 to 24) where patients receive blinded or open-label treatments based on their clinical response at week 12, and a 52-week open-label extension Period C where all patients receive the approved risankizumab maintenance treatment.xii More information on this trial can be found at www.clinicaltrials.gov (NCT06063967).xii
Patient Access and Support
AbbVie is committed to helping people access SKYRIZI and other medicines, including offering a patient support program and co-pay card that may reduce out-of-pocket costs to as little as $0 per month for eligible, commercially insured patients. For those with limited or no health insurance, AbbVie offers myAbbVie Assist, a patient assistance program that provides SKYRIZI at no charge to those who qualify. More information about this assistance program can be found at www.AbbVie.com/myAbbVieAssist.
About SKYRIZI® (risankizumab-rzaa)
SKYRIZI is an interleukin-23 (IL-23) inhibitor that blocks IL-23 by selectively binding to its p19 subunit. IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases.iii SKYRIZI is approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderately to severely active ulcerative colitis, plaque psoriasis, psoriatic arthritis and Crohn's disease.iii
SKYRIZI® (risankizumab-rzaa) U.S. Uses and Important Safety Informationiii
SKYRIZI is a prescription medicine used to treat:
moderate to severe plaque psoriasis in adults and children 6 years of age and older who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).active psoriatic arthritis in adults and children 6 years of age and older.moderately to severely active Crohn's disease in adults.moderately to severely active ulcerative colitis in adults.IMPORTANT SAFETY INFORMATION
What is the most important information I should know about SKYRIZI® (risankizumab-rzaa)?
SKYRIZI is a prescription medicine that may cause serious side effects, including:
Serious allergic reactions:
Stop using SKYRIZI and get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:fainting, dizziness, feeling lightheaded (low blood pressure)swelling of your face, eyelids, lips, mouth, tongue, or throattrouble breathing or throat tightnesschest tightnessskin rash, hivesitchingInfections:
SKYRIZI may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider may check you for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI.
Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:fever, sweats, or chillscoughshortness of breathblood in your mucus (phlegm)muscle acheswarm, red, or painful skin or sores on your body different from your psoriasisweight lossdiarrhea or stomach painburning when you urinate or urinating more often than normalDo not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients.
Before using SKYRIZI, tell your healthcare provider about all of your medical conditions, including if you:
have any of the conditions or symptoms listed in the section "What is the most important information I should know about SKYRIZI?"have an infection that does not go away or that keeps coming back.have TB or have been in close contact with someone with TB.have recently received or are scheduled to receive an immunization (vaccine). Medications that interact with the immune system may increase your risk of getting an infection after receiving live vaccines. You should avoid receiving live vaccines right before, during, or right after treatment with SKYRIZI. Tell your healthcare provider that you are taking SKYRIZI before receiving a vaccine.are pregnant or plan to become pregnant. It is not known if SKYRIZI can harm your unborn baby.are breastfeeding or plan to breastfeed. It is not known if SKYRIZI passes into your breast milk.become pregnant while taking SKYRIZI. You are encouraged to enroll in the Pregnancy Registry, which is used to collect information about the health of you and your baby. Talk to your healthcare provider or call 1-877-302-2161 or visit http://glowpregnancyregistry.com to enroll in this registry.Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of SKYRIZI?
SKYRIZI may cause serious side effects. See "What is the most important information I should know about SKYRIZI?"
Liver problems may happen while being treated for Crohn's disease or ulcerative colitis: A person with Crohn's disease who received SKYRIZI through a vein in the arm developed changes in liver blood tests with a rash that led to hospitalization. Your healthcare provider will do blood tests to check your liver before, during, and at least up to 12 weeks of treatment, and may stop treatment with SKYRIZI if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms: unexplained rash, nausea, vomiting, stomach (abdominal) pain, tiredness (fatigue), loss of appetite, yellowing of the skin and eyes (jaundice), and dark urine.
The most common side effects of SKYRIZI in people treated for Crohn's disease and ulcerative colitis include: upper respiratory infections, headache, joint pain, stomach (abdominal) pain, injection site reactions, low red blood cells (anemia), fever, back pain, urinary tract infection, and rash.
The most common side effects of SKYRIZI in people treated for plaque psoriasis and psoriatic arthritis include: upper respiratory infections, headache, feeling tired, injection site reactions, and fungal skin infections.
These are not all the possible side effects of SKYRIZI. Call your doctor for medical advice about side effects.
Use SKYRIZI exactly as your healthcare provider tells you to use it.
SKYRIZI (risankizumab-rzaa) is available in a 150 mg/mL prefilled syringe and pen, a 55 mg/0.37 mL prefilled syringe, a 600 mg/10 mL vial for intravenous infusion, and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose prefilled cartridge with on-body injector.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie may be able to help.
Visit AbbVie.com/PatientAccessSupport to learn more.
Please click here for the Full Prescribing Informationand Medication Guide.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
About AbbVie in Immunology
AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For nearly 30 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology, dermatology and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of action and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.
Today, more than 1 million patients worldwide are treated with AbbVie's immunology medicines, approved in more than 175 countries across 20+ immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines. For more information, please visit www.abbvie.com/immunology.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
References:
i. Co-primary endpoint defined as Crohn's Disease Activity Index (CDAI) score <150.
ii. Co-primary endpoint defined as decrease in SES-CD > 50% from baseline (or for patients with isolated ileal disease and a baseline SES-CD of 4, at least a 2-point reduction from baseline), as scored by a central reviewer.
iii. SKYRIZI [Package Insert]. North Chicago, IL: AbbVie Inc.
iv. Defined as CDAI of 220 to 450 and SES-CD ≥ 6 (or ≥ 4 for isolated ileal disease).
v. Keefer L, Griffith JM, Yang M, et al. Treatment satisfaction and patients' experiences with risankizumab on-body injector among adults with Crohn's disease in clinical practice: initial results from the ASPIRE-CD study. Poster P5425. Presented at: American College of Gastroenterology Annual Scientific Meeting; October 24-29, 2025; Phoenix, AZ.
vi. Data on file, AbbVie Inc. Source: ZS Associates; December 2024-February 2025.
vii. Crohn's & Colitis Foundation. The facts about inflammatory bowel diseases. Crohn's & Colitis Foundation. Published November 2014. Accessed October 13, 2026. https://www.crohnscolitisfoundation.org/sites/default/files/2019-02/Updated IBD Factbook.pdf.
viii. Mayo Clinic. Crohn's disease - Symptoms and causes. Mayo Clinic. Accessed February 23, 2026. https://www.mayoclinic.org/diseases-conditions/crohns-disease/symptoms-causes/syc-20353304.
ix. Mehta F. Report: economic implications of inflammatory bowel disease and its management. Am J Manag Care. 2016 Mar;22(3 Suppl):s51-60.
x. Kaplan G. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015 Dec;12(12):720-7. doi: 10.1038/nrgastro.2015.150.
xi. Gajendran M, et al. A comprehensive review and update on Crohn's disease. Dis Mon. 2018 Feb;64(2):20-57. doi: 10.1016/j.disamonth.2017.07.001.
xii. ClinicalTrials.gov. A Study to Evaluate Efficacy and Safety of Risankizumab Subcutaneous Induction in Participants With Moderately to Severely Active Crohn's Disease (AFFIRM). NCT06063967. Available at: https://clinicaltrials.gov/study/NCT06063967. Accessed October 13, 2026.
View original content:https://www.prnewswire.com/news-releases/us-fda-approves-subcutaneous-induction-regimen-for-abbvies-skyrizi-risankizumab-rzaa-for-adults-with-moderately-to-severely-active-crohns-disease-302918434.html
RH (RH - Free Report) closed the most recent trading day at $137.43, moving -1.94% from the previous trading session. This change lagged the S&P 500's daily loss of 0.52%. Meanwhile, the Dow experienced a drop of 1.24%, and the technology-dominated Nasdaq saw a decrease of 0.21%.
The furniture and housewares company's stock has climbed by 15.65% in the past month, exceeding the Consumer Staples sector's gain of 6.6% and the S&P 500's loss of 1.21%.
Investors will be eagerly watching for the performance of RH in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be $0.67, reflecting a 60.82% decrease from the same quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $932.39 million, up 5.5% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $5.23 per share and revenue of $3.63 billion, indicating changes of -16.85% and +5.39%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for RH. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 3.25% lower. RH is currently a Zacks Rank #3 (Hold).
Investors should also note RH's current valuation metrics, including its Forward P/E ratio of 26.81. This expresses a premium compared to the average Forward P/E of 21.41 of its industry.
One should further note that RH currently holds a PEG ratio of 2.68. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. RH's industry had an average PEG ratio of 3.04 as of yesterday's close.
The Consumer Products - Staples industry is part of the Consumer Staples sector. At present, this industry carries a Zacks Industry Rank of 200, placing it within the bottom 19% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow RH in the coming trading sessions, be sure to utilize Zacks.com.
Kraft Heinz (KHC - Free Report) closed the most recent trading day at $24.80, moving -1.16% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.52% for the day. Meanwhile, the Dow experienced a drop of 1.24%, and the technology-dominated Nasdaq saw a decrease of 0.21%.
The processed food company with dual headquarters in Pittsburgh and Chicago's shares have seen an increase of 5.16% over the last month, not keeping up with the Consumer Staples sector's gain of 6.6% and outstripping the S&P 500's loss of 1.21%.
Investors will be eagerly watching for the performance of Kraft Heinz in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on November 4, 2026. The company is forecasted to report an EPS of $0.43, showcasing a 29.51% downward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $6.05 billion, down 2.94% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $2.05 per share and a revenue of $24.53 billion, signifying shifts of -21.15% and -1.64%, respectively, from the last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Kraft Heinz. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.1% lower. Kraft Heinz presently features a Zacks Rank of #4 (Sell).
In terms of valuation, Kraft Heinz is currently trading at a Forward P/E ratio of 12.25. This expresses a discount compared to the average Forward P/E of 15.26 of its industry.
Investors should also note that KHC has a PEG ratio of 3.06 right now. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As of the close of trade yesterday, the Food - Miscellaneous industry held an average PEG ratio of 2.45.
The Food - Miscellaneous industry is part of the Consumer Staples sector. With its current Zacks Industry Rank of 202, this industry ranks in the bottom 18% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
DaVita HealthCare (DVA - Free Report) ended the recent trading session at $183.64, demonstrating a -1.32% change from the preceding day's closing price. This change lagged the S&P 500's daily loss of 0.52%. Elsewhere, the Dow lost 1.24%, while the tech-heavy Nasdaq lost 0.21%.
The kidney dialysis provider's shares have seen an increase of 6.54% over the last month, surpassing the Medical sector's gain of 3.23% and the S&P 500's loss of 1.21%.
The upcoming earnings release of DaVita HealthCare will be of great interest to investors. The company's earnings report is expected on October 29, 2026. The company's upcoming EPS is projected at $3.78, signifying a 50.60% increase compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $3.53 billion, up 3.23% from the prior-year quarter.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $14.57 per share and revenue of $14.28 billion. These totals would mark changes of +35.16% and +4.67%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for DaVita HealthCare. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. DaVita HealthCare presently features a Zacks Rank of #3 (Hold).
In terms of valuation, DaVita HealthCare is currently trading at a Forward P/E ratio of 12.77. This valuation marks a discount compared to its industry average Forward P/E of 20.58.
Investors should also note that DVA has a PEG ratio of 0.48 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. By the end of yesterday's trading, the Medical - Outpatient and Home Healthcare industry had an average PEG ratio of 1.98.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. With its current Zacks Industry Rank of 79, this industry ranks in the top 33% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Lyft (LYFT - Free Report) closed the most recent trading day at $16.91, moving -3.01% from the previous trading session. This change lagged the S&P 500's 0.52% loss on the day. Meanwhile, the Dow experienced a drop of 1.24%, and the technology-dominated Nasdaq saw a decrease of 0.21%.
Shares of the ride-hailing company have appreciated by 18.17% over the course of the past month, outperforming the Computer and Technology sector's loss of 7.7%, and the S&P 500's loss of 1.21%.
Analysts and investors alike will be keeping a close eye on the performance of Lyft in its upcoming earnings disclosure. The company's earnings report is set to go public on November 5, 2026. The company is expected to report EPS of $0.43, up 65.38% from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $1.92 billion, indicating a 13.98% upward movement from the same quarter last year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $1.65 per share and a revenue of $7.31 billion, indicating changes of +243.75% and +15.81%, respectively, from the former year.
Any recent changes to analyst estimates for Lyft should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been a 2.55% rise in the Zacks Consensus EPS estimate. Lyft is currently a Zacks Rank #3 (Hold).
Investors should also note Lyft's current valuation metrics, including its Forward P/E ratio of 10.59. This indicates a discount in contrast to its industry's Forward P/E of 14.91.
Investors should also note that LYFT has a PEG ratio of 0.53 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Internet - Services was holding an average PEG ratio of 1.63 at yesterday's closing price.
The Internet - Services industry is part of the Computer and Technology sector. With its current Zacks Industry Rank of 77, this industry ranks in the top 32% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
In the latest trading session, Bristol Myers Squibb (BMY - Free Report) closed at $61.48, marking a -2.41% move from the previous day. This move lagged the S&P 500's daily loss of 0.52%. Elsewhere, the Dow saw a downswing of 1.24%, while the tech-heavy Nasdaq depreciated by 0.21%.
Heading into today, shares of the biopharmaceutical company had gained 2.44% over the past month, lagging the Medical sector's gain of 3.23% and outpacing the S&P 500's loss of 1.21%.
Market participants will be closely following the financial results of Bristol Myers Squibb in its upcoming release. The company plans to announce its earnings on October 29, 2026. The company is forecasted to report an EPS of $1.28, showcasing a 21.47% downward movement from the corresponding quarter of the prior year. Simultaneously, our latest consensus estimate expects the revenue to be $12.56 billion, showing a 2.75% escalation compared to the year-ago quarter.
For the full year, the Zacks Consensus Estimates project earnings of $6.56 per share and a revenue of $49.85 billion, demonstrating changes of +6.67% and +3.43%, respectively, from the preceding year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Bristol Myers Squibb. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 5.69% lower within the past month. Bristol Myers Squibb currently has a Zacks Rank of #3 (Hold).
In terms of valuation, Bristol Myers Squibb is currently trading at a Forward P/E ratio of 9.61. This expresses a discount compared to the average Forward P/E of 25.2 of its industry.
Meanwhile, BMY's PEG ratio is currently 0.32. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As the market closed yesterday, the Medical - Biomedical and Genetics industry was having an average PEG ratio of 1.77.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 103, this industry ranks in the top 42% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Albemarle (ALB - Free Report) ended the recent trading session at $93.67, demonstrating a +1.22% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.52%. Elsewhere, the Dow saw a downswing of 1.24%, while the tech-heavy Nasdaq depreciated by 0.21%.
Prior to today's trading, shares of the specialty chemicals company had lost 14.51% lagged the Basic Materials sector's loss of 9.64% and the S&P 500's loss of 1.21%.
Analysts and investors alike will be keeping a close eye on the performance of Albemarle in its upcoming earnings disclosure. The company's earnings report is set to go public on November 4, 2026. The company's earnings per share (EPS) are projected to be $2.39, reflecting a 1357.89% increase from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $1.49 billion, up 14.15% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $11.19 per share and revenue of $6.09 billion. These totals would mark changes of +1516.46% and +18.41%, respectively, from last year.
Investors should also note any recent changes to analyst estimates for Albemarle. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.79% lower. As of now, Albemarle holds a Zacks Rank of #3 (Hold).
Investors should also note Albemarle's current valuation metrics, including its Forward P/E ratio of 8.27. This signifies a discount in comparison to the average Forward P/E of 15.6 for its industry.
We can additionally observe that ALB currently boasts a PEG ratio of 0.55. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Chemical - Diversified stocks are, on average, holding a PEG ratio of 1.2 based on yesterday's closing prices.
The Chemical - Diversified industry is part of the Basic Materials sector. This industry currently has a Zacks Industry Rank of 200, which puts it in the bottom 19% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Pinterest (PINS - Free Report) ended the recent trading session at $22.30, demonstrating a -2.77% change from the preceding day's closing price. This change lagged the S&P 500's 0.52% loss on the day. Elsewhere, the Dow saw a downswing of 1.24%, while the tech-heavy Nasdaq depreciated by 0.21%.
Shares of the digital pinboard and shopping tool company have appreciated by 22.49% over the course of the past month, outperforming the Computer and Technology sector's loss of 7.7%, and the S&P 500's loss of 1.21%.
Market participants will be closely following the financial results of Pinterest in its upcoming release. The company plans to announce its earnings on October 29, 2026. In that report, analysts expect Pinterest to post earnings of $0.5 per share. This would mark year-over-year growth of 31.58%. At the same time, our most recent consensus estimate is projecting a revenue of $1.2 billion, reflecting a 14.48% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of $2.02 per share and a revenue of $4.9 billion, demonstrating changes of +26.25% and +15.99%, respectively, from the preceding year.
Investors might also notice recent changes to analyst estimates for Pinterest. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Pinterest is currently sporting a Zacks Rank of #4 (Sell).
Looking at valuation, Pinterest is presently trading at a Forward P/E ratio of 11.36. For comparison, its industry has an average Forward P/E of 20.75, which means Pinterest is trading at a discount to the group.
We can also see that PINS currently has a PEG ratio of 0.43. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As of the close of trade yesterday, the Internet - Software industry held an average PEG ratio of 1.31.
The Internet - Software industry is part of the Computer and Technology sector. At present, this industry carries a Zacks Industry Rank of 83, placing it within the top 34% of over 250 industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
ROKU Investors Have Opportunity to Join Roku, Inc. Fraud Investigation with SBS Law Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Roku, Inc. (“Roku” or “the Company”) (NASDAQ: ROKU) for potential breaches of fiduciary duty on the part of its directors and management.
INVESTIGATION DETAILS: The investigation focuses on determining if the Roku board breached its fiduciary duties to shareholders. The Company to be acquired by Fox Corporation at an enterprise value of $22 billion, or $160 per share.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected]
WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261023198412/en/
Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.
Amgen (AMGN - Free Report) closed at $439.26 in the latest trading session, marking a -1.79% move from the prior day. The stock's performance was behind the S&P 500's daily loss of 0.52%. Meanwhile, the Dow experienced a drop of 1.24%, and the technology-dominated Nasdaq saw a decrease of 0.21%.
Shares of the world's largest biotech drugmaker witnessed a gain of 10.16% over the previous month, beating the performance of the Medical sector with its gain of 3.23%, and the S&P 500's loss of 1.21%.
The investment community will be paying close attention to the earnings performance of Amgen in its upcoming release. The company is slated to reveal its earnings on November 3, 2026. On that day, Amgen is projected to report earnings of $5.72 per share, which would represent year-over-year growth of 1.42%. At the same time, our most recent consensus estimate is projecting a revenue of $9.93 billion, reflecting a 3.94% rise from the equivalent quarter last year.
AMGN's full-year Zacks Consensus Estimates are calling for earnings of $22.94 per share and revenue of $38.85 billion. These results would represent year-over-year changes of +5.04% and +5.72%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for Amgen. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.02% higher. Amgen currently has a Zacks Rank of #3 (Hold).
With respect to valuation, Amgen is currently being traded at a Forward P/E ratio of 19.5. For comparison, its industry has an average Forward P/E of 25.2, which means Amgen is trading at a discount to the group.
One should further note that AMGN currently holds a PEG ratio of 3.28. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.77 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 103, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
In the latest trading session, Occidental Petroleum (OXY - Free Report) closed at $64.17, marking a +2.67% move from the previous day. This change outpaced the S&P 500's 0.52% loss on the day. At the same time, the Dow lost 1.24%, and the tech-heavy Nasdaq lost 0.21%.
Coming into today, shares of the oil and gas exploration and production company had gained 7.67% in the past month. In that same time, the Oils-Energy sector gained 5.63%, while the S&P 500 lost 1.21%.
The investment community will be closely monitoring the performance of Occidental Petroleum in its forthcoming earnings report. The company is scheduled to release its earnings on November 9, 2026. The company's earnings per share (EPS) are projected to be $1.39, reflecting a 117.19% increase from the same quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $6.73 billion, up 0.12% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $6.72 per share and revenue of $27.52 billion. These totals would mark changes of +204.07% and +8.16%, respectively, from last year.
Any recent changes to analyst estimates for Occidental Petroleum should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 8.45% rise in the Zacks Consensus EPS estimate. As of now, Occidental Petroleum holds a Zacks Rank of #2 (Buy).
In terms of valuation, Occidental Petroleum is currently trading at a Forward P/E ratio of 9.3. This expresses a discount compared to the average Forward P/E of 16.72 of its industry.
We can additionally observe that OXY currently boasts a PEG ratio of 0.73. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Oil and Gas - Integrated - United States stocks are, on average, holding a PEG ratio of 1.53 based on yesterday's closing prices.
The Oil and Gas - Integrated - United States industry is part of the Oils-Energy sector. This group has a Zacks Industry Rank of 92, putting it in the top 38% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
ServiceNow (NOW - Free Report) ended the recent trading session at $158.62, demonstrating a +1.03% change from the preceding day's closing price. This move outpaced the S&P 500's daily loss of 0.52%. At the same time, the Dow lost 1.24%, and the tech-heavy Nasdaq lost 0.21%.
Heading into today, shares of the maker of software that automates companies' technology operations had gained 13.95% over the past month, outpacing the Computer and Technology sector's loss of 7.7% and the S&P 500's loss of 1.21%.
The investment community will be closely monitoring the performance of ServiceNow in its forthcoming earnings report. The company is scheduled to release its earnings on October 28, 2026. On that day, ServiceNow is projected to report earnings of $1.02 per share, which would represent year-over-year growth of 6.25%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $4.09 billion, up 19.96% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $4.06 per share and a revenue of $16.17 billion, representing changes of +15.67% and +21.8%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for ServiceNow. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. As of now, ServiceNow holds a Zacks Rank of #5 (Strong Sell).
In terms of valuation, ServiceNow is presently being traded at a Forward P/E ratio of 38.66. This expresses a premium compared to the average Forward P/E of 16.03 of its industry.
We can additionally observe that NOW currently boasts a PEG ratio of 1.58. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As the market closed yesterday, the Computers - IT Services industry was having an average PEG ratio of 1.38.
The Computers - IT Services industry is part of the Computer and Technology sector. This group has a Zacks Industry Rank of 104, putting it in the top 43% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
In the latest trading session, Intuit (INTU - Free Report) closed at $343.39, marking a -3.24% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.52%. Meanwhile, the Dow experienced a drop of 1.24%, and the technology-dominated Nasdaq saw a decrease of 0.21%.
The stock of maker of TurboTax, QuickBooks and other accounting software has risen by 28.06% in the past month, leading the Computer and Technology sector's loss of 7.7% and the S&P 500's loss of 1.21%.
Analysts and investors alike will be keeping a close eye on the performance of Intuit in its upcoming earnings disclosure. The company is expected to report EPS of $2.47, down 26.05% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $4.3 billion, up 10.81% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates project earnings of $23.5 per share and a revenue of $23.39 billion, demonstrating changes of -3.17% and +9.07%, respectively, from the preceding year.
Investors might also notice recent changes to analyst estimates for Intuit. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.03% upward. Intuit is currently sporting a Zacks Rank of #2 (Buy).
In terms of valuation, Intuit is currently trading at a Forward P/E ratio of 15.1. For comparison, its industry has an average Forward P/E of 17.66, which means Intuit is trading at a discount to the group.
Also, we should mention that INTU has a PEG ratio of 1.15. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As the market closed yesterday, the Computer - Software industry was having an average PEG ratio of 1.49.
The Computer - Software industry is part of the Computer and Technology sector. This industry, currently bearing a Zacks Industry Rank of 55, finds itself in the top 23% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow INTU in the coming trading sessions, be sure to utilize Zacks.com.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Agustín Escobar te lleva a través de los titulares del mercado de esta semana. ======== Schwab Network ======== Empowering every investor and trader, every market day.
In the latest trading session, Accenture (ACN - Free Report) closed at $249.37, marking a -3.62% move from the previous day. This move lagged the S&P 500's daily loss of 0.52%. Elsewhere, the Dow lost 1.24%, while the tech-heavy Nasdaq lost 0.21%.
The consulting company's shares have seen an increase of 45.84% over the last month, surpassing the Computer and Technology sector's loss of 7.7% and the S&P 500's loss of 1.21%.
The investment community will be paying close attention to the earnings performance of Accenture in its upcoming release. The company is predicted to post an EPS of $3.9, indicating a 1.02% decline compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $19.35 billion, indicating a 3.22% upward movement from the same quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $14.68 per share and a revenue of $77.33 billion, representing changes of +5.08% and +4.24%, respectively, from the prior year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Accenture. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.19% higher. Currently, Accenture is carrying a Zacks Rank of #3 (Hold).
Digging into valuation, Accenture currently has a Forward P/E ratio of 17.62. This signifies a premium in comparison to the average Forward P/E of 16.03 for its industry.
Also, we should mention that ACN has a PEG ratio of 1.99. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Computers - IT Services was holding an average PEG ratio of 1.38 at yesterday's closing price.
The Computers - IT Services industry is part of the Computer and Technology sector. This group has a Zacks Industry Rank of 104, putting it in the top 43% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
Analyst’s Disclosure: I/we have a beneficial long position in the shares of NLY, AGNC either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
The Trade Desk (TTD - Free Report) closed at $13.02 in the latest trading session, marking a -1.1% move from the prior day. This change lagged the S&P 500's 0.52% loss on the day. At the same time, the Dow lost 1.24%, and the tech-heavy Nasdaq lost 0.21%.
The digital-advertising platform operator's shares have seen an increase of 4.2% over the last month, surpassing the Computer and Technology sector's loss of 7.7% and the S&P 500's loss of 1.21%.
Market participants will be closely following the financial results of The Trade Desk in its upcoming release. On that day, The Trade Desk is projected to report earnings of $0.26 per share, which would represent a year-over-year decline of 42.22%. Simultaneously, our latest consensus estimate expects the revenue to be $650.67 million, showing a 12% drop compared to the year-ago quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $1.23 per share and revenue of $2.83 billion, indicating changes of -30.51% and -2.39%, respectively, compared to the previous year.
Investors should also note any recent changes to analyst estimates for The Trade Desk. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 7% rise in the Zacks Consensus EPS estimate. At present, The Trade Desk boasts a Zacks Rank of #3 (Hold).
Investors should also note The Trade Desk's current valuation metrics, including its Forward P/E ratio of 10.67. This indicates a discount in contrast to its industry's Forward P/E of 14.91.
One should further note that TTD currently holds a PEG ratio of 0.6. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Internet - Services industry currently had an average PEG ratio of 1.63 as of yesterday's close.
The Internet - Services industry is part of the Computer and Technology sector. Currently, this industry holds a Zacks Industry Rank of 77, positioning it in the top 32% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities FuelCell Energy, Inc. (NASDAQ: FCEL) between June 24, 2026 and September 1, 2026, inclusive (the “Class Period”), of the important November 10, 2026 lead plaintiff deadline.
SO WHAT: If you purchased FuelCell securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the FuelCell class action, go to https://rosenlegal.com/cases/fuelcell-energy-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 10, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) FuelCell’s manufacturing capacity was inadequate to generate the production rate required under the capital equipment purchase agreement (“CEPA”); (2) as a result, FuelCell’s annualized production rate for deliveries under the CEPA with Fit Energy was slower than expected; (3) as a result, FuelCell was incurring higher product costs and manufacturing overhead expenses; (4) as a result of the slower production rate, FuelCell was reasonably likely to incur charges in connection with the CEPA; (5) the foregoing was a known trend affecting FuelCell’s profitability; and (6) as a result of the foregoing, defendants’ positive statements about FuelCell’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the FuelCell class action, go to https://rosenlegal.com/cases/fuelcell-energy-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827 [email protected]
www.rosenlegal.com
A senior creditors group to JetBlue Airways (JBLU.O) is working with restructuring adviser PJT Partners (PJT.N), the Wall Street Journal reported on Friday, citing people familiar with the matter.
A surge in jet fuel expenses due to the Iran war has pressured margins for US airlines despite higher airfares and steady demand for air travel.
Here are some more details:
Shares of the carrier, which have fallen 42% this year, remained volatile in extended trading
JetBlue is also in the midst of a financial and operational overhaul to reduce costs, and plans to boost its premium offerings
As of June 30, JetBlue had $1.66 billion in cash and cash equivalents along with $8.5 billion of debt and finance lease obligations, according to its filings
JetBlue and PJT did not immediately respond to Reuters requests for comment
Robinhood (HOOD -1.56%) hasn't announced any plans to launch single-stock perpetual futures on its platform yet, but there seems to be a lot of pent-up demand for them. In a recent Mizuho (MFG -1.44%) survey of over 600 active Robinhood users, 94% of respondents were willing to trade single-stock perpetual futures if they became available. Let's see why that could be bullish for Robinhood's stock -- which has declined nearly 30% over the past 12 months.
In traditional investing, investors can buy options to either buy a stock (a call) or sell it (a put) at a fixed strike price with a set expiration date. As an option approaches its expiration date, its value declines because there is less time remaining for the stock to make a major move.
Image source: Getty Images.
Single-stock perpetual futures are similar to calls and puts, but they don't have strike prices or expiration dates. Instead, an investor simply takes a bullish or bearish position in a stock, deposits cash as collateral, and chooses a leverage ratio that multiplies their gains or losses.
For example, depositing $200 at 5x leverage gives you $1,000 of exposure to an underlying stock. If that stock starts trading at $100 and rises by $10, your $1,000 position grows to $1,100 -- giving you a $100 profit on your $200 deposit. If it drops 10% to $90, it shrinks to $900 -- resulting in a $100 loss. If the stock drops near $80, the platform automatically liquidates the entire position before it consumes your entire $200 deposit.
To keep the contract's price tethered to the actual stock price without fixed strike prices or expiration dates, the buyers and sellers pay each other small funding fees. When buyers push the contract's price above the actual stock, the longs pay the shorts a periodic fee; when selling pressure pushes it lower, the shorts pay the longs a periodic fee.
HOOD Robinhood Markets$95.07-$1.51 (-1.56%)
NASDAQ · As of 4:00 PM ET 10/23/26
Why could this be bullish for Robinhood?
Robinhood already launched perpetual futures for cryptocurrencies in the U.S. and Europe this year, so it seems like a natural move to launch them for individual stocks as well. It would also complement its forward-thinking strategy of entering new markets -- including tokenized real-world assets (RWAs) and prediction markets -- before traditional brokerages.
Robinhood's stock slumped over the past year as rising interest rates and Treasury yields curbed the market's appetite for riskier investments. But many of its funded customers -- which grew 7% year over year to 28.4 million in the second quarter of 2026 -- could still be interested in using single-stock perpetual futures to trade some more volatile stocks with less capital. Therefore, expanding into that nascent market could be a bullish sign for Robinhood's stock.
Stephanie Guild, CIO of Robinhood, joins Scarlet Fu and Tom Keene on "Bloomberg Money." They discuss how she is seeing consumers take advantage of the pullback in AI, having cash on the side to invest, and how Robinhood users can now use agentic AI agents to invest on their behalf.
In the latest close session, Chipotle Mexican Grill (CMG - Free Report) was down 2.2% at $27.52. The stock fell short of the S&P 500, which registered a loss of 0.52% for the day. Meanwhile, the Dow lost 1.24%, and the Nasdaq, a tech-heavy index, lost 0.21%.
Shares of the Mexican food chain have depreciated by 12.09% over the course of the past month, underperforming the Retail-Wholesale sector's gain of 2.31%, and the S&P 500's loss of 1.21%.
Analysts and investors alike will be keeping a close eye on the performance of Chipotle Mexican Grill in its upcoming earnings disclosure. The company's earnings report is set to go public on October 28, 2026. The company is predicted to post an EPS of $0.29, indicating constancy compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $3.29 billion, indicating a 9.46% upward movement from the same quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $1.14 per share and revenue of $13 billion, indicating changes of -2.56% and +8.97%, respectively, compared to the previous year.
Investors should also note any recent changes to analyst estimates for Chipotle Mexican Grill. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.08% lower. Chipotle Mexican Grill is currently sporting a Zacks Rank of #3 (Hold).
With respect to valuation, Chipotle Mexican Grill is currently being traded at a Forward P/E ratio of 24.58. This represents a premium compared to its industry average Forward P/E of 21.23.
We can additionally observe that CMG currently boasts a PEG ratio of 1.71. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Retail - Restaurants was holding an average PEG ratio of 1.74 at yesterday's closing price.
The Retail - Restaurants industry is part of the Retail-Wholesale sector. This industry currently has a Zacks Industry Rank of 100, which puts it in the top 41% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
John Perry
Angela Aman - CEO & Director
Eliott Trencher - Executive VP, Chief Investment Officer, Interim CFO & Treasurer
A. Paratte - Executive VP & Chief Leasing Officer
Conference Call Participants
Jana Galan - BofA Securities, Research Division
Seth Bergey - Citigroup Inc., Research Division
Steve Sakwa - Evercore ISI Institutional Equities, Research Division
Blaine Heck - Wells Fargo Securities, LLC, Research Division
Nicholas Yulico - Scotiabank Global Banking and Markets, Research Division
Anthony Paolone - JPMorgan Chase & Co, Research Division
Caitlin Burrows - Goldman Sachs Group, Inc., Research Division
Michael Carroll - RBC Capital Markets, Research Division
Peter Abramowitz - Deutsche Bank AG, Research Division
Dylan Burzinski - Green Street Advisors, LLC, Research Division
John Kim - BMO Capital Markets Equity Research
Upal Rana - KeyBanc Capital Markets Inc., Research Division
Presentation
Operator
Hello, everyone. Thank you for joining us, and welcome to the Kilroy Realty Corporation Third Quarter 2026 Earnings Conference Call. [Operator Instructions]
I will now turn the call over to John Perry, Senior Vice President of Investor Relations and Capital Markets. John, please go ahead.
John Perry
Thanks, Marina. Good morning, everyone. Thank you for joining us, and welcome to the Kilroy Realty Corporation Third Quarter 2026 Earnings Call. On the call today are Angela Aman, CEO; and Eliott Trencher, EVP, CIO and Interim CFO. In addition, Rob Paratte, EVP, Chief Leasing Officer, will be available for Q&A.
Please note that some of the information that will be discussed during this call is forward-looking in nature. Please refer to the company's supplemental package for a statement regarding forward-looking information on this call and in the supplemental. This call is being webcast live on the company's website and will be available for replay. The company's earnings release and supplemental package have been filed
GXO Logistics, Inc. remains a Buy, though I lower my price target and remove share repurchase assumptions to prioritize balance sheet flexibility. Q3 revenue and EPS expectations have softened, reflecting cautious sentiment, but consensus still implies mid-single-digit growth and no full-year miss. Guidance was tightened but not raised at the midpoint; margin recovery is expected to accelerate as integration benefits materialize and contract quality improves.
David Burg - Executive VP & CFO
Rodger Levenson - Chairman, President & CEO
Conference Call Participants
Russell Elliott Gunther - Stephens Inc., Research Division
Christopher Marinac - Brean Capital, LLC, Research Division
Manuel Navas - Piper Sandler & Co., Research Division
Kelly Motta - Keefe, Bruyette, & Woods, Inc., Research Division
Sun Young Lee - TD Cowen, Research Division
Presentation
Operator
Hello, everyone. Thank you for joining us, and welcome to WSFS Financial Corporation Third Quarter Earnings Call. [Operator Instructions] I'd now like to turn the call over to your host for today, Mr. David Burg, Chief Financial Officer. Sir, please go ahead.
David Burg
Executive VP & CFO
Thank you very much. Good afternoon, and thank you for joining our third quarter 2026 earnings call. Our earnings release and earnings release supplement, which we will refer to on today's call, can be found in the Investor Relations section of our company website. With me on this call is Rodger Levenson, Chairman, President and CEO.
Prior to reviewing our financial results, I would like to read our safe harbor statement. Our discussion today will include information about our management's view of future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements due to risks and uncertainties, including, but not limited to, the risk factors in our annual report on Form 10-K and our most recent quarterly report on Form 10-Q as well as other documents we periodically file with the Securities and Exchange Commission. All comments made during today's call are subject to the safe harbor statement.
I will now turn to our financial results. During the third quarter, WSFS' performance continued to demonstrate the
New York, New York--(Newsfile Corp. - October 23, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against The Ensign Group, Inc. ("Ensign" or the "Company") (NASDAQ: ENSG) on behalf of investors that purchased or otherwise acquired Ensign securities between February 10, 2022 and June 18, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Ensign and have suffered losses, you may CLICK HERE to contact us.
The filing underscores the Monterey Peninsula's continued need for drought-proof water supplies and describes strategies to be implemented to offset project cost PACIFIC GROVE, Calif., Oct. 23, 2026 /PRNewswire/ -- Today, California American Water submitted an application to the California Public Utilities Commission (CPUC) updating the project cost estimates, a low-cost financing framework, and a proposal for rate treatment for the Monterey Peninsula Water Supply Project's desalination facilities.
Super Micro Computer, Inc. is experiencing explosive AI-driven growth, with preliminary numbers showing Q1 revenues will surge 280% YoY to ~$19 billion. Gross margin guidance has been raised to 12%-12.5%, reflecting successful product differentiation and dispelling server commoditization fears. Strategic partnerships with Cisco and Nokia, along with ongoing innovation, enhance Super Micro Computer's reach and pricing power in AI infrastructure.
Bloom Energy (BE -11.24%), a solid-oxide fuel cell systems provider, closed at $193.30, down 11.24%. Investors are locking in profits as the company reports negative operating cash flow and faces heavier expansion spending after an earnings beat-and-raise.
Trading volume reached 34.7 million shares, coming in about 117% above its three-month average of 15.9 million shares. Bloom Energy IPO'd in 2018 and has grown 672% since going public.
How the markets moved todayThe S&P 500 (^GSPC -0.52%) closed at 7,623, down 0.53%, while the Nasdaq Composite (^IXIC -0.21%) closed at 25,955, down 0.21%. Among stationary fuel cells and distributed onsite power systems for commercial and data center customers, Plug Power closed unchanged at $1.38, and FuelCell Energy closed at $11.11, down 4.06%.
What this means for investorsBloom Energy's solid-oxide fuel cell systems are an ideal solution for data center power needs. That helps explain why revenue soared 138% year over year in the third quarter. Investors were anticipating the growth, though, and some investors have decided to cash out after shares have soared more than 122% this year, even considering today's drop.
Bloom again raised its full-year revenue guidance, but investors focused on cash generation and capital spending needs. Demand is strong, and Bloom is growing production capacity.
The company reported negative free cash flow of $181 million for the quarter, spooking some investors into selling shares. The stock is now 44% off its recent high, giving investors a more reasonable valuation for those who believe the data center build-out has a long way to go.
Howard Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bloom Energy. The Motley Fool has a disclosure policy.
BOZEMAN, Mont.--(BUSINESS WIRE)---- $FICO--FICO (NYSE: FICO), global analytics software leader, today announced that it will hold its wholesale mortgage price for the FICO® Score through its tri-merge resellers at $10 for lenders and brokers enrolled in its Preferred Program. The $10 price is for a bundle of both the Classic FICO® Score, the credit score that has served as the industry standard for mortgage lending for nearly three decades, and the FICO® Score 10T, FICO's modern credit score and the most.
Fair Isaac said it is holding its price of $10 for mortgage lenders to use its FICO score, a price that is more than double that of competitor VantageScore 4.0.
Comfort Systems USA, Inc. (FIX) Q3 2026 Earnings Call October 23, 2026 11:00 AM EDT
Company Participants
Julie Shaeff - Senior VP & Chief Accounting Officer
Brian Lane - CEO & Director
William George - Executive VP & CFO
Trent McKenna - President
Conference Call Participants
Adam Thalhimer - Thompson, Davis & Company, Inc., Research Division
Adam Bubes - Goldman Sachs Group, Inc., Research Division
Sangita Jain - KeyBanc Capital Markets Inc., Research Division
Brent Thielman - Oppenheimer & Co. Inc., Research Division
Joshua Chan - UBS Investment Bank, Research Division
Timothy Mulrooney - William Blair & Company L.L.C., Research Division
Julio Romero - Sidoti & Company, LLC
Kurt Yinger - D.A. Davidson & Co., Research Division
Brian Brophy - Stifel, Nicolaus & Company, Incorporated, Research Division
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Comfort Systems USA Third Quarter 2026 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Julie Shaeff, Chief Accounting Officer. Ma'am, please go ahead.
Julie Shaeff
Senior VP & Chief Accounting Officer
Thank you, Michelle. Good morning. Welcome to Comfort Systems USA's third quarter 2026 earnings call. Our comments today as well as our press releases contain forward-looking statements within the meaning of the applicable securities laws and regulations. What we will say today is based upon the current plans and expectations of Comfort Systems USA. Those plans and expectations include risks and uncertainties that might cause actual future activities and results of our operations to be materially different from those set forth in our comments. You can read a detailed listing and commentary concerning our specific risk factors in our most recent Form 10-K and Form 10-Q as well as in our press release covering these earnings. A slide presentation is provided as a companion to our remarks
New York, New York--(Newsfile Corp. - October 23, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against The Chemours Company ("Chemours" or the "Company") (NYSE: CC) on behalf of investors that purchased or otherwise acquired Chemours securities between February 20, 2026 and August 4, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Chemours and have suffered losses, you may CLICK HERE to contact us.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
LAUSANNE, Switzerland & SAN JOSE, Calif.--(BUSINESS WIRE)--Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced the launch of Chain Reaction, a global supply chain decarbonization program designed to help supply partners cut carbon emissions, optimize factory operations and unlock shared business growth. The initiative marks an expansion of Logitech's climate strategy, providing direct operational support to help suppliers build their own decarbonization roadmaps while advancing Lo.
Hilltop Holdings (HTH -2.47%) investors had a Thursday to forget, as their stock took a bit of a dive that trading session. Hilltop released its latest set of quarterly figures after market close the day before, and these weren't exactly greeted warmly by Mr. Market when trading began the next morning. The shares closed down nearly 3% on Thursday.
A downhill quarterFor the period, Hilltop's total revenue was slightly under $310 million, down 6% year over year. Net income under generally accepted accounting principles (GAAP) declined more precipitously, at a 46% clip to $24.9 million, or $0.44 per share.
Image source: Getty Images.
Both results fell well short of the consensus analyst estimates. Collectively, pundits tracking Hilltop stock expected the company to earn just under $320 million and GAAP earnings per share (EPS) of $0.64.
In its earnings release, Hilltop characterized the quarter as "volatile" and said that the Federal Reserve's recent interest rate hike and the broader interest rate environment affected its performance.
On a brighter note, the company signaled confidence by declaring a fresh quarterly dividend matching its predecessor, at $0.22 per share. It also revealed that it spent $20 million on stock repurchases during the quarter, under a program that has roughly $86 million left under authorization until the end of the year for that purpose.
HTH Hilltop$36.36-$0.92 (-2.47%)
NYSE · As of 4:00 PM ET 10/23/26
Room for improvementIt's good that Hilltop pays a relatively high-yielding dividend (of nearly 2.2%) and is an active buyer of its own equity, because the quarter wasn't an impressive one. If I were a shareholder, I'd be particularly concerned with the clear weakness in the company's HilltopSecurities broker-dealer business and its PrimeLending mortgage unit. And I'd look elsewhere for a higher-potential financial stock.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Hershey’s is trying to win over health-conscious consumers with a new protein powder — and figure out how to get people on weight-loss drugs snacking again.
The 132-year-old candy company is working to entice consumers who have soured on sweets with a protein powder coming out in January.
With shares recently hitting a 52-week low, Hershey’s CEO Kirk Tanner has reportedly been talking one-on-one with consumers about weight loss drugs and snacks.
A woman administers a GLP-1 subcutaneous injection into her stomach tissue for weight management, obesity, or diabetes care. Matt Fowler KC – stock.adobe.com “They still love the products they love,” he told Bloomberg in an article published Friday. “They’re just eating less of them.”
With nearly 30% of obese adults in the US expected to be on appetite-suppressing GLP-1 drugs by 2035, Tanner wants to know how the company can innovate.
He pointed to rival Mars as an example.
“Today’s consumer wants new products and Mars has been delivering,” Tanner told Bloomberg.
The biggest “Payday” for Hershey’s might come from its venture into protein powder.
It partnered with protein-powder company VitaKey on the project. Details remain scarce.
A mound of Hershey’s chocolate bars. Faina Gurevich – stock.adobe.com Since Tanner came to Hershey last year, he’s upped research and development spending by 25%, with the goal of pumping out “Good & Plenty” ideas, according to Bloomberg.
Hershey’s is also expanding its gum-and-mints division to accommodate consumers battling “Ozempic breath” – the bad-breath side effect of the pound-shedding drug. Bloomberg reported gum sales at the company went up 8% earlier this year.
Hershey’s – which makes Skinny Pop, Dots Pretzels, and Pirate’s Booty – is looking to increase its savory offerings and is working on portion-controlled packaging.
The protein snack bar market has been bursting at the wrapper — it’s expected to go from $21.94 billion to $32.66 billion by 2031, an 8.2% growth rate. Rxbar, the company behind the popular golden ticket-wrapped David bars, hit a $2.25 billion valuation this year, in the biggest deal of the year in the industry, according to Forbes.
GLP-1s have posed challenges throughout the food business. Food giant Conagra has been scouring consumers’ credit-card data, social media posts and fast food orders to try to figure out what people still want to eat, according to the Wall Street Journal.
CO2NNEX(R) Digital Platform for Integrated Management of the Environmental Value of Sustainable Liquid Fuel (HVO) to Commence Operation in Demonstration of Sustainable Fuels Certificates Scheme
TOKYO, Oct 23, 2026 - (JCN Newswire) - Osaka Gas Co., Ltd. ("Osaka Gas") and Mitsubishi Heavy Industries, Ltd. ("MHI") today commenced operation of CO2NNEX?(1), a digital platform jointly developed and deployed by the two companies, under the 2026 Project for the Establishment of Environmental Value Certification Scheme, etc. (Demonstration Project for Consideration of the Building of a Scheme for Certification and Transfer of Environmental Value of Sustainable Fuels) implemented by the Agency for Natural Resources and Energy of the Ministry of Economy, Trade and Industry of Japan ("ANRE") (hereinafter referred to as "the Scheme Demonstration")(2). In the Scheme Demonstration, CO2NNEX will be used in consideration of the system requirements needed for the processes of issuing, transferring, and retiring sustainable fuel certificates.
Toward the widespread deployment of sustainable fuels (e-gasoline, SAF, HVO(3), e-methane, biogas, etc.), the adoption of sustainable fuels certificates scheme to certify and manage the environmental value of those fuels is being considered. The Scheme Demonstration is being conducted to examine issues in the adoption and the design of this scheme.
Osaka Gas and MHI aim to create value in the following forms through CO2NNEX, with a view to the widespread deployment of Sustainable liquid fuels and full-scale operation of the system in the future.
(1) Realization of digitalization and operational efficiency improvement for procedures, including collaboration with third-party certification bodies
Exchange of information between applicants and third-party certification bodies for procedures such as application, verification, and issuing of certificates will be completed on CO2NNEX. The introduction of a digital platform will enable the building of processes for prompt verification and issuance of certificates, minimizing the workload involved in procedures such as document handling. It will also enable reliable management of certificates without manual operations as the results of the digital authorization performed by the third-party certification bodies will be automatically reflected in transfer, retirement, and management processes after the certificates are issued on the system.
(2) Prevention of double-counting, enabling appropriate management and enhanced reliability of environmental value A mechanism to prevent double-counting of environmental value through the use of digital trust technology will be built into the system. System requirements will also be organized with the aim of contributing to a highly reliable certificate system design that will ensure traceability.
ANRE is also conducting a demonstration of a sustainable fuels certificates scheme for e-methane and biogas in the area of utility gas. Osaka Gas and MHI are making considerations for the use of CO2NNEX by the parties involved in that demonstration for e-methane and biogas. Going forward, Osaka Gas and MHI will contribute to the practical application of various sustainable fuels through the building and provision of system requirements with a high level of utility and reliability to meet the needs of future social infrastructure in the areas of both gas and liquid fuels.
(1) CO2NNEX:
CO2NNEX is a digital platform developed by MHI for the visualization and management of CO2 supply chain. In the Scheme Demonstration, Osaka Gas and MHI will use CO2NNEX to jointly consider the system requirements needed for the operational processes for issuing, transferring, and retiring sustainable fuels certificates. This system also has functions for transfer and management of attribute data for clean gas certificates used to certify the environmental value of e-methane and biogas, which have been used for purposes such as Expo 2025 and Nagaoka Methanation Demonstration."CO2NNEX" is a registered trademark of MHI in Japan and other countries.
For details, see the following press release:
"Operations Started for the Nagaoka Methanation Demonstration Utilizing the CO2NNEX? Digital Platform for Transfer and Management of e-Methane Clean Gas Certificates" (June 4, 2026)
https://www.osakagas.co.jp/en/whatsnew/__icsFiles/afieldfile/2026/06/03/260604_1.pdf
https://www.mhi.com/news/260604.html
(2) 2026 Project for the Establishment of Environmental Value Certification Scheme, etc. (Demonstration Project for Consideration of the Building of a System for Certification and Transfer of Environmental Value of Sustainable Fuels):
A demonstration conducted by the Ministry of Economy, Trade and Industry in fiscal 2026 for the phased establishment of sustainable fuels certificates scheme.
For details, see the following document:11th Environmental Improvement Working Group, Public-Private Joint Meeting to Promote the Adoption of Next-Generation Fuels (March 11, 2026)Document 5: Direction of Considerations on sustainable Fuels Certificates Scheme in the Next Fiscal Year
https://www.meti.go.jp/shingikai/energy_environment/e_fuel/kankyo_wg/pdf/011_05_00.pdf(in Japanese only)
(3) HVO:
Hydrotreated vegetable oils, a biofuel produced by reacting vegetable oil or used cooking oil with hydrogen at a high temperature and pressure (hydrotreating) to improve properties such as oxidative stability. Mainly expected to be used as a substitute for diesel oil.
About Osaka Gas
Daigas Group, based on its Energy Transition 2050 released in February 2025, will work to develop technologies and services that contribute to a carbon-neutral society, actively address climate change and other social challenges, and aim to be a corporate group that contributes to the further advancement of everyday life and business.
About Mitsubishi Heavy Industries
Since its founding in 1884, Mitsubishi Heavy Industries (MHI) Group has been a global leader in engineering and manufacturing, sincerely addressing societal challenges and supporting people's lives. By integrating cutting-edge knowledge with the advanced technological capabilities cultivated over its long history, we will continue to tackle social issues through technology and contribute to the realization of a safe and prosperous society. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com.
About MHI Group
Mitsubishi Heavy Industries (MHI) Group is one of the world's leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com.
Source: Mitsubishi Heavy Industries (MHI)
Copyright 2026 JCN Newswire . All rights reserved.
Disclosures
I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.
NEC Presents Phase I/II Results for Individualized Oral Neoantigen Therapy, NECVAX-NEO1 at ESMO 2026
Phase I/II NECVAX-NEO1 trial in patients with triple-negative breast cancer confirm its potential safety and immunogenicity and provide clinical proof-of-concept for the use of this investigational oral bacteria-based DNA neoantigen therapy in high-risk early-stage cancer patients including the perioperative setting as well.
TOKYO, Japan, Oct 23, 2026 - (JCN Newswire) - NEC Bio will be presenting results from the Phase I/II TNBC clinical trial of its orally administered individualized neoantigen therapy, NECVAX-NEO1, used in combination with checkpoint inhibitors (CPIs) and chemotherapy for patients with triple-negative breast cancer (TNBC). The findings are being presented in an e-poster at the ESMO Congress in Madrid, Spain, from October 23 to 27, 2026.
NECVAX-NEO1 is an AI powered individualized bacteria-based oral DNA therapy that combines IMMUNASIGHT(r), NEC Bio's proprietary AI based neoantigen prediction platform for identifying the most immunogenic patient-specific neoepitopes, with TORAPRIME(R), its proprietary oral bacterial neoantigen delivery platform. This therapy is designed to activate a patient's immune system, prompting a T-cell response that can precisely target and eliminate tumor cells based on an individual's unique neoantigens.
In the first cohort of the phase I/II study, 8 patients with TNBC were treated with NECVAX-NEO1 in a neoadjuvant setting. All patients were treated with 2 courses of neoadjuvant chemotherapy and pembrolizumab before the planned surgery. After 12 weeks of chemotherapy/pembrolizumab, NECVAX-NEO1 was added on top, with an optional adjuvant treatment phase after surgery. NECVAX-NEO1 on top of chemotherapy/immunotherapy was generally well tolerated. Five patients achieved pathological complete response at surgery, accompanied by corresponding biomarker changes. In all patients, immunogenic neoepitopes used in NECVAX-NEO1 were detected, as demonstrated by ELISPOT analysis.
Regarding the results of the clinical study, Dr. Heinz Lubenau, CEO of NEC Bio Therapeutics, commented, "Our clinical Phase I/II data are demonstrating promising immune responses in the neoadjuvant treatment of early-stage TNBC patients. The results are encouraging, so we are extending the trial to n=28 patients, including patients in the U.S., as we recently received IND approval to conduct a clinical trial in the country. The additional patients in cohort 2 are being treated with a higher dose of NECVAX-NEO1 on top of Keynote-522 standard of care regimen, which includes pembrolizumab. We look forward to further evaluation of NECVAX-NEO1 as a potential treatment option for cancer patients with high medical need."
Akira Kitamura, CEO, NEC Bio, further commented, "The results presented at ESMO 2026 are an important accomplishment that further strengthens NEC Bio's confidence in the potential of NECVAX-NEO1 as an individualized neoantigen therapy. By combining our proprietary AI-powered neoantigen discovery platform, IMMUNASIGHT(R) with a differentiated neoantigen delivery platform TORAPRIME(R), we aim to deliver highly individualized treatment approaches for patients with cancer. These findings support our continued commitment to advancing innovative therapies that have the potential to improve patient outcomes and expand the possibilities of precision treatment in oncology."
Details of the poster are below:
Poster title: Phase I/II study of neoadjuvant personalized vaccination with NECVAX-NEO1, in combination with pembrolizumab and chemotherapy in early-stage triple-negative breast cancer, evaluating safety, immunogenicity, and preliminary clinical activity NCT06631092
Authors: Peter A. Fasching, Katharina Keller, Oliver Schleicher, Carlo Fremd, Laura Michel, Michael Platten, Isabel Poschke, Ingrid Hulsmeyer, Margarida Garcia, Alvaro Aranguren, Kaidre Bendjama, Daiki Mori, Heinz Lubenau, Andreas Schneeweiss
Poster Number: 4694eP
Date: 23 October 2026
The poster may also be found here: https://www.nec-bio.com/en_DD/img/20261022_ESMO2026_NECVAX-NEO1_05_DE_poster.pdf
Trial details can also be viewed at: NCT06631092
NECVAX-NEO1 is currently under evaluation at additional clinical trial sites in several European countries.
About IMMUNASIGHT(R)
IMMUNASIGHT(R) is NEC Bio's AI-powered neoantigen discovery platform designed to identify and prioritize clinically relevant immune targets for next-generation immunotherapies. By modeling the complete antigen presentation pathway, from mutation identification and processing to presentation, together with immunogenicity, IMMUNASIGHT(R) helps researchers narrow thousands of potential targets to those most likely to elicit meaningful anti-tumor immune responses. The cloud-native platform supports scalable, reproducible, and rapid analysis for oncology research and therapeutic development. IMMUNASIGHT(R) is registered in certain jurisdictions
About TORAPRIME(R)
TORAPRIME(R) is NEC Bio's proprietary oral bacteria-based delivery platform that uses attenuated bacteria to deliver DNA encoding selected neoantigens through the gut immune system. Following oral administration, the platform is designed to induce neoantigen-specific T cell responses and support systemic anti-tumor immune responses. TORAPRIME(R) is the delivery technology underlying NECVAX-NEO1. TORAPRIME(R) is registered in certain jurisdictions.
About NEC Bio
NEC Bio is the biotechnology arm of NEC Corporation, headquartered in the Netherlands, and focused on leveraging state-of-the-art AI technologies to address the world's most pressing healthcare challenges. Leveraging cutting-edge science, data, and innovation, NEC Bio is dedicated to developing personalized therapies designed to transform patient outcomes and improve quality of life globally. With a growing international footprint, NEC Bio includes subsidiaries such as NEC OncoImmunity in Oslo, Norway, and NEC Bio Therapeutics in Mannheim, Germany-each contributing specialized expertise across immunotherapy, precision medicine, and translational research. Together, these entities form a collaborative ecosystem committed to accelerating innovation from discovery to patient impact.
To learn more, visit www.nec-bio.com and follow us on LinkedIn for the latest updates.
About NEC Bio Therapeutics
NEC Bio Therapeutics, established in Mannheim, Germany, focuses on the clinical strategy and development, as well as planning and execution of clinical trials in the oncology area. It is a subsidiary of NEC Bio, the biotech arm of NEC Corporation.
About NEC Corporation
The NEC Group leverages technology to create social value and promote a more sustainable world where everyone has the chance to reach their full potential. NEC Corporation was established in 1899. Today, the NEC Group's approximately 110,000 employees utilize world-leading AI, security, and communications technologies to solve the most pressing needs of customers and society.
For more information, please visit https://www.nec.com, and follow us on LinkedIn and YouTube.
Source: NEC Corporation
Copyright 2026 JCN Newswire . All rights reserved.
Disclosures
I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.
Grocery delivery giant Instacart has held preliminary discussions with Uber and DoorDash about a potential sale, The Information reported Friday.
An investment bank is helping Instacart, which is worth about $13 billion, assess its options, according to the report, which cited people familiar with the matter.
A takeover could fetch roughly $16 billion to $17 billion if a buyer pays a 30% to 40% premium, an estimate based on recent public tech deals.
Instacart, which was valued at $39 billion during the pandemic, is exploring a sale at a time when its market value stands at roughly $12 billion. REUTERS The potential sale comes as Uber and DoorDash expand their grocery delivery businesses and pursue multibillion-dollar acquisitions across the food delivery industry.
An Instacart spokesperson declined to comment when reached by The Post.
A takeover by either company could face antitrust scrutiny because of its competing grocery delivery operations.
Antitrust concerns helped derail DoorDash’s 2021 discussions to acquire Instacart at a valuation of $40 billion to $50 billion, The Information previously reported.
The discussions broke down partly over concerns about securing regulatory approval during the Biden administration, according to the report.
Instacart struck a deal with Uber in 2024 to offer restaurant delivery powered by Uber Eats through its grocery app.
Last year, Uber began using Instacart’s Carrot Ads technology to offer sponsored grocery placements on Uber Eats.
DoorDash previously held talks to acquire Instacart in 2021, but the discussions collapsed partly over antitrust concerns. Mojahid Mottakin – stock.adobe.com Earlier discussions between Uber and Instacart failed to advance as Uber pursued other acquisitions, The Information reported.
Instacart’s expansion into advertising has yet to close the revenue growth gap with Uber and DoorDash.
Instacart was valued at $39 billion in a 2021 private funding round amid a pandemic-era boom in grocery delivery.
By the time the company went public in 2023, its valuation had tumbled to roughly $10 billion.
Instacart shares have gained roughly 70% since the IPO. Its revenue growth slowed from 19% in 2023 to 11% in each of the following two years.
Uber, which has a market value of roughly $135 billion, is among the potential buyers that have held preliminary discussions with Instacart, according to The Information. ink drop – stock.adobe.com Instacart generated $480 million in free cash flow during the second quarter, while revenue increased 14% from a year earlier to just over $1 billion.
The company has said it plans to devote most of its free cash flow this year to repurchasing shares.
DoorDash recorded a 28% revenue increase in 2025, compared with 18% at Uber, whose business also includes ride-hailing.
Amazon, which owns Whole Foods, has also expanded its grocery delivery operations.
DoorDash, valued at roughly $80 billion, acquired Deliveroo and restaurant software firm SevenRooms in 2025, three years after buying European delivery platform Wolt for about $8 billion.
Uber, with a market value of about $135 billion, has agreed this year to pay roughly $15 billion for Delivery Hero and more than $2 billion for workplace catering service ezCater.
The Information reported that Uber’s recent dealmaking could complicate a potential bid for Instacart.
Instacart’s talks with prospective buyers have yet to produce an agreement, and a sale remains uncertain, according to the report.
San Diego, California--(Newsfile Corp. - October 23, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of sellers of Dun & Bradstreet Holdings, Inc. (NYSE: DNB) common stock between May 13, 2025 and August 26, 2025, inclusive (the "Class Period"), including holders who exchanged shares of Dun & Bradstreet common stock in the Merger with Clearlake Capital Group, L.P., and holders of Dun & Bradstreet common stock as of the May 9, 2025 record date for the special meeting of stockholders and whose shares were voted on, or entitled to vote on, the merger with Clearlake. Dun & Bradstreet is a global provider of business decision data and analytics.
The complaint alleges that Dun & Bradstreet's sale was engineered by the Company's Executive Chairman William P. Foley to relieve an acute liquidity crisis at Cannae Holdings, Inc., D&B's largest stockholder, which Foley also chaired-and to defeat an activist proxy contest that threatened Foley's control of Cannae.
Investors who suffered significant losses during the Class Period may be eligible to participate in the lawsuit and should contact Robbins LLP before the November 10, 2026, lead plaintiff deadline.
Listen to our podcast.
Why Was Dun & Bradstreet Sued?
According to the complaint, on or about March 23, 2025, Dun & Bradstreet agreed to be acquired by affiliates of Clearlake for $9.15 per share in cash. According to the complaint, to obtain the stockholder approval required to consummate the merger, Dun & Bradstreet issued a definitive proxy statement on Schedule 14A on May 13, 2025 (the "Proxy"). Dun & Bradstreet stockholders allegedly voted to approve the merger on June 12, 2025, and the merger closed on August 26, 2025.
Plaintiff alleges that defendants made false and/or misleading statements and/or failed to disclose material facts in Dun & Bradstreet's March 23, 2025, merger announcement and in the Proxy.
Specifically, defendants failed to disclose: (i) the actual impetus for the sale: the liquidity crisis and activist threat confronting Cannae, and Foley's determination to convert Dun & Bradstreet, Cannae's largest holding, into cash quickly to address these issues; (ii) that several alternatives to a whole-company sale were worth materially more than $9.15 per share; (iii) the false board approval of the March Projections; and (iv) the advisor conflicts in the sales process.
Who May Be Eligible to Participate in the Dun & Bradstreet Class Action?
The lawsuit seeks to represent investors who sold Dun & Bradstreet Holdings, Inc. common stock between May 13, 2025 and August 26, 2025. Investors who suffered losses during that period may have legal rights under the federal securities laws.
What Is a Lead Plaintiff?
The lead plaintiff is a court-appointed investor who represents the interests of all class members throughout the litigation. Stockholders who wish to lead the class action should contact Robbins LLP for information prior to the November 10, 2026, lead plaintiff deadline.
Serving as lead plaintiff is not required to share in any potential recovery. Investors who do not seek appointment may remain absent class members if the case proceeds and later resolves successfully.
Does It Cost Anything to Participate?
No. Robbins LLP represents investors on a contingency fee basis.
Contact Robbins LLP
Investors seeking additional information about the Dun & Bradstreet Holdings, Inc. securities class action may contact Robbins LLP by submitting an inquiry, emailing attorney Aaron Dumas, Jr., or calling (800) 350-6003.
Why Robbins LLP?
A recognized leader in shareholder rights litigation, Robbins LLP represents investors in securities fraud and shareholder derivative litigation. We have helped restore more than $2 billion in value to shareholders and secured some of the largest recoveries in shareholder derivative litigation history.
"Companies have an obligation to provide investors with complete and accurate information so that markets can function fairly and efficiently," said Brian J. Robbins, Founding Partner of Robbins LLP.
To be notified if a class action against Dun & Bradstreet Holdings, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
Facebook
LinkedIn
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320692
Source: Robbins LLP
Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
New York, New York--(Newsfile Corp. - October 23, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Honeywell Aerospace Inc. ("Honeywell Aerospace" or the "Company") (NASDAQ: HONA) on behalf of investors that purchased or otherwise acquired Honeywell Aerospace common stock between June 29, 2026 and September 1, 2026 (the "Class Period").
CLICK HERE TO JOIN THE CASE
If you are an investor in Honeywell Aerospace and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.
DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than November 23, 2026 for an opportunity to be lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.
On August 5, 2026, after the market closed, the complaint alleges that Honeywell Aerospace slashed its full year 2026 guidance and announced second quarter 2026 earnings, reporting that net income fell 70% year-over-year and adjusted earnings per share declined 32% year-over-year. On this news, Honeywell Aerospace's share price fell $47.17 or 23.16%, to close at $156.47 on August 6, 2026.
On September 1, 2026 the U.S. Department of Justice Department announced that Honeywell Aerospace agreed to pay over $2 million to settle False Claims Act allegations of failing to comply with cybersecurity requirements in a U.S. Department of Defense contract. On this news, Honeywell Aerospace's stock price fell $3.87 or 2.45%, to close at $154.24 per share on September 1, 2026.
The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose (1) that a small percentage of the Company's suppliers had a "disproportionate impact" on sales; (2) that those suppliers were suffering supply constraints; (3) that the foregoing was reasonably likely to have a material unfavorable impact on sales and profitability; and (4) that the Company was under investigation for potential violations of the False Claims Act for failing to comply with cybersecurity requirements for government contracts.
CLICK HERE TO LEARN MORE
WHY CONTACT KAPLAN FOX?
Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.
Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.
For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.
If you have any questions about this Notice, your rights, or your interests, please contact:
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
New York, New York--(Newsfile Corp. - October 23, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the "Class Period").
CLICK HERE TO JOIN THE CASE
If you are an investor in Beta Bionics and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.
DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than November 3, 2026 for an opportunity to be lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.
Beta Bionics is a commercial-stage medical device company, serving patients with diabetes through the iLet Bionic Pancreas insulin pump ("iLet"), an automated insulin delivery system. The complaint alleges that throughout the Class Period, Beta Bionics received thousands of complaints from iLet customers, including numerous reports of serious, life-threatening hypoglycemia caused by device malfunctions that required hospitalization to treat. The root cause of these malfunctions was allegedly iLet's extremely aggressive dosing algorithm.
The truth was allegedly revealed through a series of disclosures starting on January 8, 2026 when Beta Bionics surprised investors with a miss on the key metric of new iLet patient starts, which was followed by a 37% one-day stock price decline. Finally, on February 24, 2026, the full truth was allegedly revealed when the U.S. Food and Drug Administration (the "FDA") publicly released its warning letter detailing a litany of violations and Defendants' failure to correct them, and contradicting months of Defendants' public statements that all back-filed complaints were for entirely benign issues. According to the complaint, the warning letter made clear that Defendants' prior interpretation of FDA reporting requirements had not been reasonable, and had excluded numerous serious patient incidents that clearly should have been reported.
CLICK HERE TO LEARN MORE
WHY CONTACT KAPLAN FOX?
Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.
Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.
For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.
If you have any questions about this Notice, your rights, or your interests, please contact:
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
New York, New York--(Newsfile Corp. - October 23, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Innventure, Inc. ("Innventure" or the "Company") (NASDAQ: INV) on behalf of investors that purchased or otherwise acquired Innventure securities between November 17, 2025 and August 13, 2026 (the "Class Period").
CLICK HERE TO JOIN THE CASE
If you are an investor in Innventure and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.
DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than October 27, 2026 for an opportunity to be lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.
On November 17, 2025, the start of the Class Period, the complaint alleges Innventure announced that its subsidiary Accelsius had entered into an agreement with DarkNX under which DarkNX would deploy Accelsius' NeuCool technology across a new 300MW AI data center campus in Ontario, Canada.
On August 13, 2026, however, according to the complaint, the Company announced it was "suspending [its] previously communicated expectations regarding Accelsius' 2026 revenue and cash flow targets and shifting [its] focus." Additionally, the complaint alleges the Company filed its Form 10-Q with the SEC the same day, disclosing "the deployment site identified in the Dark NX purchase order is no longer available" and that "Accelsius has removed the DarkNX project from its internal bookings." On this news, Innventure's stock price fell $1.98 per share, or 55%, to close at $1.62 per share on August 14, 2026.
The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that "(1) Accelsius' alleged transformative deal with DarkNX was unlikely to come to fruition as no evidence of DarkNX constructing or facilitating a large scale AI data center existed; (2) as a result, the Company's stated revenue and cash flow targets for Accelsius in 2026 were overstated; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis."
CLICK HERE TO LEARN MORE
WHY CONTACT KAPLAN FOX?
Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.
Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.
For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.
If you have any questions about this Notice, your rights, or your interests, please contact:
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
New York, New York--(Newsfile Corp. - October 23, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Millrose Properties, Inc. ("Millrose" or the "Company") (NYSE: MRP) on behalf of investors that purchased or otherwise acquired Millrose securities between February 7, 2025 and October 2, 2026 (the "Class Period").
CLICK HERE TO JOIN THE CASE
If you are an investor in Millrose and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.
DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than December 8, 2026 for an opportunity to be lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.
The Class Period begins on February 7, 2025, the day the spin-off of Millrose from Lennar became effective. According to the complaint, the prospectus for the spin-off stated "[w]e do not, and will not, have any lease agreements with respect to the Transferred Assets and the Supplemental Transferred Assets, do not intend to enter into any lease agreements in the foreseeable future and do not, and will not, have any tenants or occupants on any of the properties in the Real Estate Portfolio."
According to the complaint, on October 2, 2025, Hunterbrook Media issued a report revealing that Millrose purchased $200 million worth of finished homes from Lennar, an entity that controls Millrose, with the intent of leasing those properties on the rental market. The Hunterbrook Media report allegedly further revealed that Millrose is making a loss on those rental properties. On this news, the price of Millrose shares fell 8.5%, or $2.10 per share, on October 5, 2026 according to the complaint.
The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that despite representations to the contrary (i) Millrose's objectives were not limited to engaging in land purchases, horizontal development, and homesite option purchase arrangements for Lennar and potentially other homebuilders and developers; and (ii) Millrose would in fact enter into lease agreements and would have tenants in its properties.
CLICK HERE TO LEARN MORE
WHY CONTACT KAPLAN FOX?
Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.
Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.
For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.
If you have any questions about this Notice, your rights, or your interests, please contact:
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
On its third quarter of 2026 earnings call, held on Oct. 22, 2026, Boyd Gaming (BYD -0.80%) announced adjusted revenue growth of 2% following property portfolio adjustments. The company's ability to fund large developments while repurchasing shares provides a clear blueprint for compounding value. Three things management said stand out.
Boyd Gaming reduced its total share count by 9.4% over the past year through stock repurchases. Management aims to maintain this pace by allocating $150 million each quarter toward buybacks alongside quarterly dividends.
We plan to continue targeting approximately $150 million in shares per quarter placing us on track inclusive of dividends to return more than $680 million to shareholders this year, representing approximately $9.80 per share in value for our shareholders.
-- Josh Hirsberg, Chief Financial Officer2. Major Resort Developments Power the Long-Term Growth PipelineThe company is expanding its physical footprint outside core markets through major resort construction. Its project in Norfolk, Virginia, serves as the anchor for expansion into new gaming regions.
In Virginia, our resort development in Norfolk remains on time and on budget for a November 2027 opening, and we expect to celebrate the topping off by the end of this year.
-- Keith E. Smith, President and Chief Executive Officer3. Low Leverage Preserves Financial Flexibility for Strategic OpportunitiesMaintaining traditional leverage of 2.2 times operating cash flow allows the company to fund development projects and shareholder payouts without risking balance sheet stability. That balance sheet discipline provides protection against temporary regional demand shifts.
Given our strong free cash flow, we are able to make capital investments and return capital to shareholders while maintaining a strong balance sheet. We ended the quarter with traditional leverage of 2.2x and lease adjusted leverage of 2.7x.
-- Josh Hirsberg, Chief Financial OfficerLooking AheadLocal economic fundamentals in Southern Nevada remain favorable, with population growth and job creation driving consistent core play. The company relies on its diversified property portfolio, owned real estate assets, and conservative leverage to sustain cash flow while keeping close watch on promotional discipline and destination travel patterns.
Throughout this year, our Las Vegas locals results have been supported by continued growth in play from Southern Nevada residents, and the strong underlying fundamentals of the Southern Nevada economy gives us confidence these trends will continue.
-- Keith E. Smith, President and Chief Executive OfficerAs capital projects in Virginia and property remodels across Las Vegas near completion, Boyd Gaming enters its next growth phase with significant balance sheet capacity and disciplined capital allocation.
In conclusion, our consistent operating performance, strong balance sheet, and robust free cash flow position us well to continue creating long term value for our shareholders.
-- Josh Hirsberg, Chief Financial OfficerThe Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
New York, New York--(Newsfile Corp. - October 23, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Duolingo, Inc. ("Duolingo" or the "Company") (NASDAQ: DUOL) on behalf of investors that purchased or otherwise acquired Duolingo Class A common stock between May 2, 2025 and February 26, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Duolingo and have suffered losses, you may CLICK HERE to contact us.
